GlassScriptPhysician profile
Susan Ormsby Burns
NPI 1144603283
$5,837.17
in general payments reported to CMS, 2019-2025
31 companies · $1,014 in 2025
The $1,014 reported for 2025 was more than what 87% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,017 · 2022: $1,514 · 2023: $935 · 2024: $1,357 · 2025: $1,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,305.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,007.48 | 2021-2024 | Farxiga, Saphnelo |
| Vifor Pharma, INC. | $420.04 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $397.62 | 2023-2025 | |
| Amgen INC. | $339.91 | 2022-2025 | Tavneos |
| Mallinckrodt Hospital Products INC. | $263.53 | 2022-2025 | Terlivaz |
| Alexion Pharmaceuticals, INC. | $252.56 | 2022-2025 | Ultomiris |
| Sk Life Science, INC. | $245.30 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.42 | 2024 | Jardiance |
| Axsome Therapeutics, INC. | $217.19 | 2023-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $183.44 | 2025 | Prevymis |
| Abbott Laboratories | $163.69 | 2021-2024 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $139.38 | 2024-2025 | Livtencity |
| Akebia Therapeutics INC | $133.89 | 2021-2024 | Vafseo |
| Neurelis, INC. | $127.77 | 2023 | Valtoco |
| Kyowa Kirin, INC. | $127.47 | 2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.95 | 2025 | Caplyta |
| Actelion Pharmaceuticals US, INC. | $125.00 | 2024 | Uptravi, Opsumit |
| Lundbeck LLC | $124.99 | 2024 | Vyepti |
| Pfizer INC. | $124.07 | 2022-2025 | |
| Horizon Therapeutics Plc | $122.24 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $121.12 | 2023 | Dupixent |
| Mdd US Operations, LLC | $118.03 | 2023 | Apokyn |
| Otsuka America Pharmaceutical, INC. | $116.71 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $116.47 | 2022 | |
| Idorsia Pharmaceuticals US INC | $103.84 | 2023 | Quviviq |
| Tg Therapeutics, INC. | $98.52 | 2024 | |
| Incyte Corporation | $95.71 | 2022 | |
| Daiichi Sankyo INC. | $87.83 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $50.84 | 2021 | |
| Bard Peripheral Vascular, INC. | $36.73 | 2021 | |
| Fresenius USA Marketing, INC. | $15.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Burns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.